|
MAO INHIBITORS PROLONG & INTENSIFY THE ANTICHOLINERGIC EFFECTS OF ANTIHISTAMINICS
|
|
ZIPRASIDONE INHIBITS THE EFFECT OF OTHER DRUG
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
CONCOMITANT USE SHOULD BE AVOIDED
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|